Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials

被引：0
作者：
Abdelrahman Ibrahim Abushouk
Ahmed Elmaraezy
Amro Aglan
Reham Salama
Samar Fouda
Rana Fouda
Ammar M. AlSafadi
机构：
[1] Faculty of Medicine,
[2] Ain Shams University,undefined
[3] NovaMed Medical Research Association,undefined
[4] Faculty of Medicine,undefined
[5] Al-Azhar University,undefined
[6] Faculty of Medicine,undefined
[7] Tanta University,undefined
[8] Faculty of Medicine,undefined
[9] Benha University,undefined
[10] Faculty of Medicine,undefined
[11] Zagazig University,undefined
[12] Faculty of Medicine,undefined
[13] Damascus University,undefined
来源：
BMC Neurology | / 17卷
关键词：
Bapineuzumab; Passive immunotherapy; Alzheimer’s disease; Dementia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Memantine treatment for Japanese patients with moderate to severe Alzheimer's disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
    Kishi, Taro
    Matsunaga, Shinji
    Iwata, Nakao
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 2915 - 2922
  • [42] Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
    Imbimbo, Bruno P.
    Ottonello, Simone
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    Greco, Antonio
    Seripa, Davide
    Pilotto, Alberto
    Panza, Francesco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (02) : 135 - 149
  • [43] Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
    Qiao, Yue
    Chi, Yuewei
    Zhang, Qingyuan
    Ma, Ying
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [44] A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease
    Brody, Mark
    Liu, Enchi
    Di, Jianing
    Lu, Ming
    Margolin, Richard A.
    Werth, John L.
    Booth, Kevin
    Shadman, Anna
    Brashear, H. Robert
    Novak, Gerald
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (04) : 1509 - 1519
  • [45] Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
    Egan, Michael F.
    Kost, James
    Tariot, Pierre N.
    Aisen, Paul S.
    Cummings, Jeffrey L.
    Vellas, Bruno
    Sur, Cyrille
    Mukai, Yuki
    Voss, Tiffini
    Furtek, Christine
    Mahoney, Erin
    Mozley, Lyn Harper
    Vandenberghe, Rik
    Mo, Yi
    Michelson, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (18) : 1691 - 1703
  • [46] Efficacy and safety of neuromodulation for apathy in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
    Jin, Yushan
    Li, Jinbiao
    Xiao, Bo
    JOURNAL OF PSYCHIATRIC RESEARCH, 2024, 171 : 17 - 24
  • [47] A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil
    Pisani, Sara
    Mueller, Christoph
    Huntley, Jonathan
    Aarsland, Dag
    Kempton, Matthew J.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2021, 36 (10) : 1471 - 1487
  • [48] Psychometric Properties of the Dependence Scale in Large Randomized Clinical Trials of Patients With Mild and Moderate Alzheimer's Disease
    Wyrwich, Kathleen W.
    Auguste, Priscilla
    Buchanan, Jacqui
    Rudell, Katja
    Lacey, Loretto
    Leibman, Christopher
    Symonds, Tara
    Brashear, H. Robert
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2014, 29 (07): : 620 - 629
  • [49] Recruitment and adherence of randomized controlled trials for mild cognitive impairment: A systematic review and meta-analysis
    Xu, Zijun
    Sun, Wen
    Zhang, Dexing
    Wong, Samuel Yeungshan
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2020, 35 (10) : 1141 - 1150
  • [50] Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer's Disease: A Bayesian Network Meta-Analysis
    Zhang, Tingting
    Liu, Nanyang
    Cao, Hongfu
    Wei, Wei
    Ma, Lina
    Li, Hao
    FRONTIERS IN PHARMACOLOGY, 2020, 11
12345